Yoshikatsu Koga

Dr. Yoshikatsu Koga

Department of Strategic Programs, Exploratory Oncology Research & Clinical Trial Center (EPOC), National Cancer Center, Kashiwa, Japan
orcid

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 May 2019 in Cells
Verified
Journal Article
Open access
PDF file
Yoshikatsu KogaYoshikatsu Koga
Yoshikatsu Koga
AOAtsushi Ochiai
Atsushi Ochiai
Patient-derived xenograft (PDX) models are used as powerful tools for understanding cancer biology in PDX clinical trials and co-clinical trials. In this systematic review, we focus on PDX clinical trials or co-clinical trials for drug development in solid tumors and summarize the utility of PDX models in the development of anti-cancer drugs, as well as the challenges involved in this approach, following the preferred reporting items for systematic reviews and meta-analyses (PRISMA) guidelines. Recently, the assessment of drug efficacy by PDX clinical and co-clinical trials has become an important method. PDX clinical trials can be used for the development of anti-cancer drugs before clinical trials, with their efficacy assessed by the modified response evaluation criteria in solid tumors (mRECIST). A few dozen cases of PDX models have completed enrollment, and the efficacy of the drugs is assessed by 1 × 1 × 1 or 3 × 1 × 1 approaches in the PDX clinical trials. Furthermore, co-clinical trials can be used for personalized care or precision medicine with the evaluation of a new drug or a novel combination. Several PDX models from patients in clinical trials have been used to assess the efficacy of individual drugs or drug combinations in co-clinical trials.

1 August 2018 in Journal of Controlled Release
Verified
Journal Article
Open access
RTRyo Tsumura
Ryo Tsumura
SMShino Manabe
Shino Manabe
HTHiroki Takashima
Hiroki Takashima
Yoshikatsu KogaYoshikatsu Koga
Yoshikatsu Koga
MYMasahiro Yasunaga
Masahiro Yasunaga
YMYasuhiro Matsumura
Yasuhiro Matsumura
Antibody-drug conjugates (ADCs) are currently considered to be promising agents for cancer therapy. However, especially in solid tumors, the uneven distribution of ADCs would decrease their efficacy in clinical studies. We suggest that in addition to optimizing ADC components, such as the linker structure and anticancer agent, it is necessary to consider the distribution of the ADC within tumor tissue. In this study, we established three kinds of anti-tissue factor (TF) ADCs: 1849ADC with a low kd, 444ADC with an intermediate kd, and 1084ADC with a high kd. All three of the anti-TF ADCs exhibited almost the same in vitro cytotoxicity and pharmacological and biochemical characteristics, although the binding kinetics parameters differed. In vivo, all ADCs exerted equivalent antitumor effects against small BxPC3 tumors. However, on larger BxPC3 tumors, 1084ADC (higher kd) exerted higher antitumor activity than 1849ADC (lower kd). Furthermore, immunofluorescence staining indicated that 1084ADC was distributed throughout the whole tumor, whereas 1849ADC was mainly localized close to tumor vessels. We conclude that the ADC with a higher kd increased the antitumor effect of because it penetrated and distributed evenly throughout the entire solid tumor. These findings highlight the importance of the kd of a mAb in ADC design.

28 December 2016 in Oncotarget
Verified
Journal Article
Open access
PDF file
NYNobuyoshi Yamazaki
Nobuyoshi Yamazaki
Yoshikatsu KogaYoshikatsu Koga
Yoshikatsu Koga
HTHirokazu Taniguchi
Hirokazu Taniguchi
MKMotohiro Kojima
Motohiro Kojima
YKYukihide Kanemitsu
Yukihide Kanemitsu
YMYasuhiro Matsumura
Yasuhiro Matsumura
High expression of miR-181c as a predictive marker of recurrence in stage II colorectal cancer

16 July 2024 in Cancer Discovery
Verified
Journal Article
Open access
PDF file
THTadayoshi Hashimoto
Tadayoshi Hashimoto
YNYoshiaki Nakamura
Yoshiaki Nakamura
TFTakao Fujisawa
Takao Fujisawa
MIMitsuho Imai
Mitsuho Imai
TSTaro Shibuki
Taro Shibuki
TYTakayuki Yoshino
Takayuki Yoshino
The SCRUM-Japan MONSTAR-SCREEN consortium is a nationwide molecular profiling project employing artificial intelligence–driven multiomics analyses for patients with advanced malignancies, aiming to develop novel therapeutics and diagnostics and deliver effective drugs to patients. Concurrently, studies assessing molecular residual disease–based precision medicine for resectable solid tumors, including CIRCULATE-Japan, are ongoing. The substantial data generated by these platforms are stored within a state-of-the-art supercomputing infrastructure, VAPOR CONE. Since 2015, our project has registered over 24,000 patients as of December 2023. Among 16,144 patients with advanced solid tumors enrolled in MONSTAR-SCREEN projects, 5.0% have participated in matched clinical trials, demonstrating a 29.2% objective response rate and 14.8-month median survival (95% CI, 13.4–16.3) for patients treated in the matched clinical trials. Notably, patients who received matched therapy demonstrated significantly prolonged overall survival compared with those who did not (hazard ratio 0.77; 95% confidence interval, 0.71–0.83). Significance: Our nationwide molecular profiling initiative played pivotal roles in facilitating the enrollment of patients with advanced solid tumors into matched clinical trials and highlighted the substantial survival benefits of patients treated with matched therapy. We aim to facilitate an industry–academia data-sharing infrastructure ecosystem, fostering new drug discovery paradigms and precision medicine.

17 September 2017 in Bioengineering
Verified
Journal Article
Open access
PDF file
MYMasahiro Yasunaga
Masahiro Yasunaga
SMShino Manabe
Shino Manabe
Atsushi TsujiAtsushi Tsuji
Atsushi Tsuji
MFMasaru Furuta
Masaru Furuta
KOKoretsugu Ogata
Koretsugu Ogata
YMYasuhiro Matsumura
Yasuhiro Matsumura
Antibody-drug conjugate (ADC), as a next generation of antibody therapeutics, is a combination of an antibody and a drug connected via a specialized linker. ADC has four action steps: systemic circulation, the enhanced permeability and retention (EPR) effect, penetration within the tumor tissue, and action on cells, such as through drug delivery system (DDS) drugs. An antibody with a size of about 10 nm has the same capacity for passive targeting as some DDS carriers, depending on the EPR effect. In addition, some antibodies are capable of active targeting. A linker is stable in the bloodstream but should release drugs efficiently in the tumor cells or their microenvironment. Thus, the linker technology is actually a typical controlled release technology in DDS. Here, we focused on molecular imaging. Fluorescent and positron emission tomography (PET) imaging is useful for the visualization and evaluation of antibody delivery in terms of passive and active targeting in the systemic circulation and in tumors. To evaluate the controlled release of the ADC in the targeted area, a mass spectrometry imaging (MSI) with a mass microscope, to visualize the drug released from ADC, was used. As a result, we succeeded in confirming the significant anti-tumor activity of anti-fibrin, or anti-tissue factor-ADC, in preclinical settings by using DDS and molecular imaging.

1 March 2021 in Clinical and Translational Gastroenterology
Verified
Journal Article
Open access
MSMasau Sekiguchi
Masau Sekiguchi
YKYasuo Kakugawa
Yasuo Kakugawa
HIHiroaki Ikematsu
Hiroaki Ikematsu
KHKinichi Hotta
Kinichi Hotta
KKKenichi Konda
Kenichi Konda
TMTakahisa Matsuda
Takahisa Matsuda
INTRODUCTION: Noninvasive colorectal cancer (CRC) screening methods with higher sensitivity for advanced colorectal neoplasia (ACN) than the fecal immunochemical test (FIT) alone are warranted. This study aimed to elucidate the diagnostic performance of a risk stratification score calculated using baseline individual characteristics and its combination with FIT for detecting ACN. METHODS: This cross-sectional analysis of data from a prospective cohort in Izu Oshima, Japan, included asymptomatic individuals age 40–79 years who underwent both 2-day quantitative FIT and screening colonoscopy. The 8-point risk score, calculated based on age, sex, CRC family history, body mass index, and smoking history, was assessed. Colonoscopy results were used as reference. RESULTS: Overall, 1,191 individuals were included, and 112 had ACN. The sensitivity and specificity of the 1-/2-day FIT (cutoff: 50–200 ng Hb/mL) for ACN were 17.9%–33.9% (4.9%–22.0% for right-sided ACN) and 91.8%–97.6%, respectively. The risk score's c-statistic for ACN was 0.66, and combining the score (cutoff: 5 points) with 1-/2-day FIT (cutoff: 50–200 ng Hb/mL) yielded a sensitivity and specificity for ACN of 46.4%–56.3% (43.9%–48.8% for right-sided ACN) and 76.6%–80.8%, respectively. The specificity of the risk score and FIT combination for all adenomatous lesions was 82.4%–86.4%. DISCUSSION: The 8-point risk score remarkably increased the sensitivity for ACN, particularly for right-sided ACN. Although the specificity decreased, it was still maintained at a relatively high level. The risk score and FIT combination has the potential to become a viable noninvasive CRC screening option.